The DAX crumbled slightly by 4 from on 10.063 points. Even the Euro Stoxx 50 was for something. While oil tracks were under pressure, put technology stocks with a takeover offer from Softbank for the British ARM too. However, individual sectors and companies might be affected, such as the travel sector. The shares of the sector traded little changed, although TUI duties 1.4 percent. The shares of the Spanish banking giant fell by 2.8 percent. Carry affected. At Fraport investors could put a question mark behind the annual targets, since they depended heavily from the airport in Antalya. For Ströer Turkey is one of the core markets, and at the Eon sales could be or IPO plans of the Turkish participation Enerjisa shelved. Fraport and Metro gave for something Ströer attracted to it. Here surprised a takeover offer from Softbank of Japan for the British ARM Holdings. ARM jumped by almost 41 percent upward. The high premium that is willing to pay Softbank, also drove the market valuation of other European companies in the semiconductor industry such as STMicroelectronics, Infineon and Dialog Semiconductor upwards. Dealers pointed to media reports about the accounting. The Svenska Dagbladet writes, citing sources familiar with the matter, Ericsson distend the results by including expected revenues and uncertain on. “All indicators are slightly above our estimates. However, the positive side, especially the order intake,” said one trader. With an increase of 8.3 percent, the prognosis of his house by 7 percent had been quite clearly exceeded. Especially the unusually high profitability was highlighted: the profit margin is 27.3 percent by a significant 240 basis points above the consensus estimates. As a result, therefore also lies EBITDA by 638 million Swiss francs to 11 percent higher than the consensus forecast. Also Symrise benefited and laid 2.0 percent. Instead slightly higher is now expected with falling profits. Dealers refer to a very pessimistic forecast of the container ship operator. “In particular, the statement that the recent rebound in freight rates may not be sustainable, is poison for the course,” said one trader. The drug Gazyva for the treatment of blood cancer in a Phase III study did not reach the intended target. “The growth expectations Gazyva are very high, but on a very low absolute level,” said one trader. So we expect the market to date, with an approximately 60 percent increase in sales in the second quarter compared to the previous quarter. Although sales is in line with expectations, but margins have not met the forecasts. “The price volatility is likely to remain high until clarity about the planned Monsanto takeover is” said one trader. This increased to 125 dollars per share bid will not sway the Monsanto shareholders also will grant Monsanto Leverkusen at this price no insight into the books.